These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 26912077)
1. Outer membrane vesicles as platform vaccine technology. van der Pol L; Stork M; van der Ley P Biotechnol J; 2015 Sep; 10(11):1689-706. PubMed ID: 26912077 [TBL] [Abstract][Full Text] [Related]
2. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485 [TBL] [Abstract][Full Text] [Related]
3. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470 [TBL] [Abstract][Full Text] [Related]
5. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis. Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743 [TBL] [Abstract][Full Text] [Related]
6. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X mBio; 2019 Sep; 10(5):. PubMed ID: 31506309 [TBL] [Abstract][Full Text] [Related]
7. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. van der Ley P; van den Dobbelsteen G Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281 [TBL] [Abstract][Full Text] [Related]
8. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555 [TBL] [Abstract][Full Text] [Related]
9. Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis. Gerritzen MJH; Martens DE; Uittenbogaard JP; Wijffels RH; Stork M Sci Rep; 2019 Mar; 9(1):4716. PubMed ID: 30886228 [TBL] [Abstract][Full Text] [Related]
10. Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis. Li Q; Zhou G; Fei X; Tian Y; Wang S; Shi H Appl Environ Microbiol; 2023 Mar; 89(3):e0204722. PubMed ID: 36809058 [TBL] [Abstract][Full Text] [Related]
11. Continuous production of Neisseria meningitidis outer membrane vesicles. Gerritzen MJH; Stangowez L; van de Waterbeemd B; Martens DE; Wijffels RH; Stork M Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9401-9410. PubMed ID: 31676919 [TBL] [Abstract][Full Text] [Related]
13. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197 [TBL] [Abstract][Full Text] [Related]
14. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles. Salverda ML; Meinderts SM; Hamstra HJ; Wagemakers A; Hovius JW; van der Ark A; Stork M; van der Ley P Vaccine; 2016 Feb; 34(8):1025-33. PubMed ID: 26801064 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Sanders H; Feavers IM Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800 [TBL] [Abstract][Full Text] [Related]
17. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313 [TBL] [Abstract][Full Text] [Related]
18. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Holst J Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231 [TBL] [Abstract][Full Text] [Related]
19. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]